Brexit Ambiguity A Top Priority For Bayer's New UK & Ireland CEO
Lars Bruening, who recently succeeded Alexander Moscho as Bayer's CEO for the UK and Ireland, talks to Scrip about Brexit uncertainties and fostering the right dialog between pharma and healthcare systems.
You may also be interested in...
Merck & Co. will build a new innovation hub in London – an act described by the UK government as a major strategic investment – despite widespread Brexit ambiguity and a potentially unstable economic situation ahead for the soon-to-be ex-EU nation.
Bayer's pharma head Dieter Weinand talks about his biggest issues with current value-based pricing assessments for new drugs and how companion diagnostics will pave the way to easier pricing of oncology therapies.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.